Indivior backs FY view, warns of generic rival hit; shares fall

(Reuters) - Shares of drugmaker Indivior Plc fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat version of its blockbuster film-based opioid addiction treatment.The company stuck to its full-year forecast on Wednesday, but warned it could take a hit if the rival drug from Dr. Reddy's Laboratories Ltd comes to market this year.Indivior's shares nearly halved in value on Tuesday and sank to an all-time..